Table 3.

Laboratory assays in the study group, depending on the type of disease-modifying therapy without the assessment of healthy controls.

Parameters	IFN-β1ad	IFN-β1b	GAe	NTf	FGg	p
N	22	17	5	7	12
NOx a [µM]	2.25 ± 0.71	1.90 ± 0.69	1.58 ± 0.35	1.65 ± 0.31	1.52 ± 0.31	0.018
IL-1β/IL-1F2b [pg/mL]	1.43 ± 0.34	1.56 ± 0.60	1.71 ± 0.41	2.19 ± 1.27	1.51 ± 0.56	0.78
CRPc [mg/L]	2.43 ± 3.14	1.88 ± 1.71	1.72 ± 1.12	0.95 ± 0.79	1.81 ± 2.5	0.79

A: nitric oxide (nitrite and nitrate); b: interleukin; c: C-reactive protein; d: interferon beta; e: glatiramer acetate; f: natalizumab; g: fingolimod.